Dogwood Therapeutics, Inc. (DWTX) Form SCHEDULE 13D/A — Oct 21, 2026
Dogwood Therapeutics disclosed in a Schedule 13D/A that controlling shareholder Sealbond Limited agreed on October 19, 2026 to purchase 4,098,360 shares at $1.22 per share in a private placement, roughly $5.0 million in gross proceeds, with closing expected by October 29, 2026. The purchase lifts Sealbond's direct stake to approximately 63.9% of the 34,129,553 shares outstanding, and its parent CK Life Sciences Int'l. (Holdings) to approximately 72.3% on an aggregate basis. Dogwood also signed a registration rights agreement requiring it to file a resale registration statement within 15 days.
Key figures
- Gross Proceeds
- 5000000
- Offering Price
- 1.22
- Shares Offered
- 4098360
- Shares Outstanding
- 34129553
- Closing date
- on or prior to October 29, 2026
- Conjoint percent
- 8.3%
- Sealbond percent
- 63.9%
- Ck life sciences percent
- 72.3%
- Registration filing deadline
- 15 days after agreement date
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.